Evidence map›Paper›PMID 40316741›Full record

ArticleOncogene2025

Multiple anti-tumor programs are activated by blocking BAD phosphorylation.

John Maringa Githaka, Raven Kirschenman, Namrata Patel, Namita Tripathi, Joy Wang, Laiji Li, Heather Muranyi, Leila Pirayeshfard, Rachel Montpetit, Darryl D Glubrecht and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

John Maringa GithakaDepartment of Biochemistry, University of Alberta, Edmonton, AB, Canada. maringa@ualberta.ca.ORCID http://orcid.org/0000-0003-1974-0415
Raven KirschenmanDepartment of Biochemistry, University of Alberta, Edmonton, AB, Canada.
Namrata PatelDepartment of Biochemistry, University of Alberta, Edmonton, AB, Canada.
Namita TripathiDepartment of Biochemistry, University of Alberta, Edmonton, AB, Canada.
Joy WangDepartment of Biochemistry, University of Alberta, Edmonton, AB, Canada.
Laiji LiDepartment of Biochemistry, University of Alberta, Edmonton, AB, Canada.
Heather MuranyiDepartment of Biochemistry, University of Alberta, Edmonton, AB, Canada.
Leila PirayeshfardDepartment of Biochemistry, University of Alberta, Edmonton, AB, Canada.ORCID http://orcid.org/0000-0001-6090-4325
Rachel MontpetitDepartment of Biochemistry, University of Alberta, Edmonton, AB, Canada.
Darryl D GlubrechtDepartment of Oncology, University of Alberta, Edmonton, AB, Canada.
E Paul LernerDepartment of Surgery, University of Alberta, Edmonton, AB, Canada.ORCID http://orcid.org/0000-0002-3638-3475
Troy PerryDepartment of Surgery, University of Alberta, Edmonton, AB, Canada.
Nika N DanialDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-4842-1827
P Nick NationAnimal Pathology Services (APS) Ltd., Canmore, AB, Canada.
Roseline GodboutDepartment of Oncology, University of Alberta, Edmonton, AB, Canada.ORCID http://orcid.org/0000-0002-4779-9265
Ing Swie GopingDepartment of Biochemistry, University of Alberta, Edmonton, AB, Canada. igoping@ualberta.ca.ORCID http://orcid.org/0000-0001-6355-827X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Bcl-2 family member BAD is a candidate disease modulator because it stimulates apoptosis in a cell context basis and inhibits cell migration during normal mammary gland morphogenesis. This activity depends on 3 key regulatory serines (S75, 99, 118) in the unphosphorylated state. Given that developmental programs are often hijacked in cancer, we hypothesized that BAD would impede breast cancer progression. We generated breast cancer mouse models representing loss-of-function or phosphorylation deficient mutations (PyMT-Bad

Indexed as

bcl-Associated Death ProteinBreast NeoplasmsAnimalsApoptosisCell Line, TumorCell MovementFemaleHumansMiceMice, KnockoutPhosphorylationBAD protein, humanBad protein, mousebcl-Associated Death Protein

Identifiers

PMID40316741

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.